BioSpace News Archive

Business

Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced financial results for the third quarter of 2022 and provided a general business update.

November 3, 2022
·
11 min read
BioMidwest

Renalytix to Present at Stifel Healthcare Conference 2022

Renalytix plc announced the Company will participate in the Stifel Healthcare Conference to be held November 15-16, 2022 at the Lotte New York Palace Hotel.

November 3, 2022
·
1 min read
Business

Amryt Reports Q3 2022 Financial and Operational Results

Amryt provides a business update and announces unaudited financial results for the third quarter ended September30, 2022.

November 3, 2022
·
84 min read
Business

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

Keros Therapeutics, Inc. provided a business update and reported financial results for the quarter ended September 30, 2022.

November 3, 2022
·
8 min read
Business

Athenex Provides Third Quarter 2022 Financial Results and Business Update

Athenex, Inc. provided a corporate and financial update for the third quarter ended September 30, 2022.

November 3, 2022
·
14 min read
Biotech Bay

Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced a $25 million equity investment from Bristol Myers Squibb and a term loan facility with access to up to $125 million from Hercules Capital, Inc.

November 3, 2022
·
6 min read
VABYSMO® (faricimab injection) receives positive CADTH recommendation for the treatment of Diabetic Macular Edema (DME) in adults

Hoffmann-La Roche Limited is pleased to announce that on October 31, 2022, the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee recommended VABYSMO® for public reimbursement.

November 3, 2022
·
5 min read
BioMidwest

Bio-Techne to Present at the Credit Suisse 31st Annual Healthcare Conference

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST.

November 3, 2022
·
2 min read
Biotech Beach

Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation

Ainos, Inc. announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha formulation, VELDONA®.

November 3, 2022
·
8 min read
Biotech Beach

ACELYRIN, INC. to Present at Upcoming Investor Conferences - November 03, 2022

ACELYRIN, INC. announced that its Co-founder and Chief Executive Officer Shao-Lee Lin, MD, PhD will present at the following upcoming investor conferences:

November 3, 2022
·
1 min read